Intravenous Glycoprotein IIb / IIIa Antagonists: Their Benefits, Problems and Future Developments

E-ISSN： 1873-4286|10|14|1577-1585

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.10, Iss.14, 2004-05, pp. : 1577-1585

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Platelet Glycoprotein IIb/IIIa Receptor Antagonists: Current Concepts and Future Directions

By Ferguson J.J. Zaqqa M.

Drugs, Vol. 58, Iss. 6, 1999-12 ,pp. : 965-982

Adis International

Access to resources Recommend Favorite

Platelet glycoprotein IIb/IIIa receptor antagonists

By Casserly I.P. Moliterno D.J.

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 3, 2000-03 ,pp. : 419-433

Informa Healthcare

Access to resources Recommend Favorite

Oral glycoprotein IIb/IIIa antagonists unsuccessful

Inpharma, Vol. 1, Iss. 1345, 2002-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Current Issues with Glycoprotein IIb-IIIa Antagonists

Current Drug Targets, Vol. 12, Iss. 12, 2011-11 ,pp. : 1813-1820

Bentham Science Publishers

Access to resources Recommend Favorite

The use of glycoprotein IIb/IIIa receptor antagonists in percutaneous coronary intervention results in both short- and long-term benefits

By Adis International Limited

Drugs & Therapy Perspectives, Vol. 20, Iss. 10, 2004-10 ,pp. : 7-10

Adis International

Access to resources Recommend Favorite